Hemab Therapeutics Holdings, Inc. (COAG) stock
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.06+0.01 (+0.01%)
Close on Nov 17, 2026Market cap $1.82BP/E –Yield –
Hemab Therapeutics cash
Cash and short-term investments held at the end of each period.
Hemab Therapeutics's cash was $430.24M at Sep 30, 2026. For fiscal 2025 it was $185.49M.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.49M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $430.24M | – |
| Q2 FY2026 | Jun 30, 2026 | $457.46M | – |
| Q1 FY2026 | Mar 31, 2026 | $163.53M | – |
| Q4 FY2025 | Dec 31, 2025 | $185.49M | – |
See a number that looks wrong?